MNMD

Mind Medicine

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 4

Sell signal 0

stock price surged significantly

consensus rating "Buy"

Upward Gap

EPS Beats Expectation

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About MNMD

Mind Medicine (Mindmed) Inc.

A clinical stage biopharmaceutical company developing novel products to treat brain health disorders

Industry

Pharmaceutical

Established Date

Invalid Date

Listing Date

04/27/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.mindmed.co

Security Type

Common stock

Office address

One World Trade Center, Suite 8500, New York, New York 10007

Business

Introduction

Mind Medicine (MindMed) Inc., incorporated in Canada. They are a clinical-stage neurodrug development company that develops psychedelic-based drug candidates through rigorous scientific and clinical trials. Their mission is to discover, develop and deploy psychedelic-inspired drugs and therapies to treat psychiatry, neurology, addiction, pain, and potentially other disorders such as anxiety, substance abuse and withdrawal, and adult attention deficit disorder.

Company Financials

EPS

MNMD has released its 2024 Q4 earnings. EPS was reported at -0.41, versus the expected -0.28, missing expectations. The chart below visualizes how MNMD has performed over recent quarters, highlighting trends in earnings surprises.